77 related articles for article (PubMed ID: 20528623)
1. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
Zamboni WC; Eiseman JL; Strychor S; Rice PM; Joseph E; Zamboni BA; Donnelly MK; Shurer J; Parise RA; Tonda ME; Yu NY; Basse PH
J Liposome Res; 2011 Mar; 21(1):70-80. PubMed ID: 20528623
[TBL] [Abstract][Full Text] [Related]
2. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
3. STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.
Yu NY; Conway C; Pena RL; Chen JY
Anticancer Res; 2007; 27(4B):2541-5. PubMed ID: 17695551
[TBL] [Abstract][Full Text] [Related]
4. Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors.
Zamboni WC; Maruca LJ; Strychor S; Zamboni BA; Ramalingam S; Edwards RP; Kim J; Bang Y; Lee H; Friedland DM; Stoller RG; Belani CP; Ramanathan RK
J Liposome Res; 2011 Jun; 21(2):158-65. PubMed ID: 20626314
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
[TBL] [Abstract][Full Text] [Related]
6. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL
Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
9. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
J Clin Pharmacol; 2012 Feb; 52(2):180-94. PubMed ID: 21233302
[TBL] [Abstract][Full Text] [Related]
11. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
12. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies.
Zamboni WC; Ramalingam S; Friedland DM; Edwards RP; Stoller RG; Strychor S; Maruca L; Zamboni BA; Belani CP; Ramanathan RK
Clin Cancer Res; 2009 Feb; 15(4):1466-72. PubMed ID: 19190127
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
18. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
19. Mechanism-based model characterizing bidirectional interaction between PEGylated liposomal CKD-602 (S-CKD602) and monocytes in cancer patients.
Wu H; Ramanathan RK; Zamboni BA; Strychor S; Ramalingam S; Edwards RP; Friedland DM; Stoller RG; Belani CP; Maruca LJ; Bang YJ; Zamboni WC
Int J Nanomedicine; 2012; 7():5555-64. PubMed ID: 23112576
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
